Top Back to top

A multi-centre, multinational, prospective observational registry to collect safety and outcome data in patients diagnosed with severe hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation (HSCT) and treated with Defitelio®

Study number:
DF VOD-2013-03-REG
Short title:
Study status:
Deadline for data collection:
Study design:
Prospective, multinational study - 1 cohort (under defibrotide)
Primary objective:
The main objective of the registry is to assess the incidence rate of specific serious adverse events (SAEs) of interest (including fatalities) in patients with severe hepatic VOD post-HSCT treated with Defitelio®
Key inclusion criteria:
- Any consenting patient with a diagnosis of severe VOD post-HSCT (treated with defibrotide)
- Any consenting patient receiving defibrotide for any other condition (VOD Prophylaxis, non-severe VOD…) in HSCT context
United Kingdom
Principal investigator:
Pr Mohamad Mohty
Principal investigator email:
EBMT Study coordinator:
Jessica Lemaitre
Study coordinator email:

Need help?

The personal data provided will be processed according to the General Data Protection Regulation (GDPR 2016/679 ) and incorporated to a file property of EBMT which will be allocated in the EEA (European Economic Area) or in countries that are provided with the same level of protection for privacy such as countries that adhere to EU-US and Swiss-US Privacy Shield Frameworks.
Data Subjects have the right of access to his or her data and the right to rectification of any inaccurate or incomplete personal data. The Data Subject also has the right to withdraw consent, this wish will be respected, and the personal will no longer be made available. If the processing operation is unlawful the Data Subject has the right to request deletion of that data. Please write to